- Home
- YRD vs GHRS Comparison
YRD vs GHRS Comparison
Compare YRD & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YRD
- GHRS
- Stock Information
- Founded
- YRD 2012
- GHRS 2018
- Country
- YRD China
- GHRS Ireland
- Employees
- YRD N/A
- GHRS N/A
- Industry
- YRD Finance: Consumer Services
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- YRD Finance
- GHRS Health Care
- Exchange
- YRD Nasdaq
- GHRS Nasdaq
- Market Cap
- YRD 554.6M
- GHRS 583.1M
- IPO Year
- YRD 2015
- GHRS 2021
- Fundamental
- Price
- YRD $6.28
- GHRS $10.60
- Analyst Decision
- YRD
- GHRS Strong Buy
- Analyst Count
- YRD 0
- GHRS 8
- Target Price
- YRD N/A
- GHRS $30.63
- AVG Volume (30 Days)
- YRD 91.8K
- GHRS 146.4K
- Earning Date
- YRD 06-20-2025
- GHRS 05-08-2025
- Dividend Yield
- YRD 6.23%
- GHRS N/A
- EPS Growth
- YRD N/A
- GHRS N/A
- EPS
- YRD 2.48
- GHRS N/A
- Revenue
- YRD $795,426,969.00
- GHRS N/A
- Revenue This Year
- YRD N/A
- GHRS N/A
- Revenue Next Year
- YRD N/A
- GHRS N/A
- P/E Ratio
- YRD $2.50
- GHRS N/A
- Revenue Growth
- YRD 18.59
- GHRS N/A
- 52 Week Low
- YRD $4.12
- GHRS $6.00
- 52 Week High
- YRD $9.20
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- YRD 48.71
- GHRS 59.36
- Support Level
- YRD $6.13
- GHRS $9.81
- Resistance Level
- YRD $6.50
- GHRS $11.50
- Average True Range (ATR)
- YRD 0.27
- GHRS 0.72
- MACD
- YRD 0.02
- GHRS 0.23
- Stochastic Oscillator
- YRD 61.74
- GHRS 89.60
About YRD Yiren Digital Ltd.
Yiren Digital Ltd is an advanced, AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.